Literature DB >> 16847401

HIV/AIDS preventive vaccine 'prime-boost' phase III trial: foundations and initial lessons learned from Thailand.

Supachai Rerks-Ngarm, Arthur E Brown, Chirasak Khamboonruang, Prasert Thongcharoen, Prayura Kunasol.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16847401     DOI： 10.1097/01.aids.0000237362.26370.f8

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


× No keyword cloud information.
  12 in total

Review 1.  Weighing the gold in the gold standard: challenges in HIV prevention research.

Authors:  Nancy S Padian; Sandra I McCoy; Jennifer E Balkus; Judith N Wasserheit
Journal:  AIDS       Date:  2010-03-13       Impact factor: 4.177

Review 2.  The good and evil of complement activation in HIV-1 infection.

Authors:  Qigui Yu; Richard Yu; Xuebin Qin
Journal:  Cell Mol Immunol       Date:  2010-03-15       Impact factor: 11.530

3.  Molecular evolution of the HIV-1 Thai epidemic between the time of RV144 immunogen selection to the execution of the vaccine efficacy trial.

Authors:  Gustavo H Kijak; Sodsai Tovanabutra; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Chirapa Eamsila; Prayura Kunasol; Chirasak Khamboonruang; Prasert Thongcharoen; Chawetsan Namwat; Nakorn Premsri; Michael Benenson; Patricia Morgan; Meera Bose; Eric Sanders-Buell; Robert Paris; Merlin L Robb; Deborah L Birx; Mark S De Souza; Francine E McCutchan; Nelson L Michael; Jerome H Kim
Journal:  J Virol       Date:  2013-04-10       Impact factor: 5.103

4.  A novel assay for antibody-dependent cell-mediated cytotoxicity against HIV-1- or SIV-infected cells reveals incomplete overlap with antibodies measured by neutralization and binding assays.

Authors:  Michael D Alpert; Lisa N Heyer; David E J Williams; Jackson D Harvey; Thomas Greenough; Maria Allhorn; David T Evans
Journal:  J Virol       Date:  2012-08-29       Impact factor: 5.103

5.  The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope.

Authors:  Mark S de Souza; Silvia Ratto-Kim; Weerawan Chuenarom; Alexandra Schuetz; Somsak Chantakulkij; Bessara Nuntapinit; Anais Valencia-Micolta; Doris Thelian; Sorachai Nitayaphan; Punnee Pitisuttithum; Robert M Paris; Jaranit Kaewkungwal; Nelson L Michael; Supachai Rerks-Ngarm; Bonnie Mathieson; Mary Marovich; Jeffrey R Currier; Jerome H Kim
Journal:  J Immunol       Date:  2012-04-23       Impact factor: 5.422

6.  International collaboration between US and Thailand on a clinical trial of treatment for HIV-associated cryptococcal meningitis.

Authors:  L O Zimmer; T L Nolen; S Pramanpol; D Wallace; M E Walker; P Pappas; P Chetchotisakd
Journal:  Contemp Clin Trials       Date:  2009-11-06       Impact factor: 2.226

Review 7.  Stakeholder Engagement in HIV Cure Research: Lessons Learned from Other HIV Interventions and the Way Forward.

Authors:  Ying-Ru Lo; Carissa Chu; Jintanat Ananworanich; Jean-Louis Excler; Joseph D Tucker
Journal:  AIDS Patient Care STDS       Date:  2015-05-18       Impact factor: 5.078

Review 8.  Current progress in the development of a prophylactic vaccine for HIV-1.

Authors:  Lena J Gamble; Qiana L Matthews
Journal:  Drug Des Devel Ther       Date:  2010-12-22       Impact factor: 4.162

9.  Will circumcision provide even more protection from HIV to women and men? New estimates of the population impact of circumcision interventions.

Authors:  Timothy B Hallett; Ramzi A Alsallaq; Jared M Baeten; Helen Weiss; Connie Celum; Ron Gray; Laith Abu-Raddad
Journal:  Sex Transm Infect       Date:  2010-10-21       Impact factor: 3.519

10.  Persisting with prevention: the importance of adherence for HIV prevention.

Authors:  Helen A Weiss; Judith N Wasserheit; Ruanne V Barnabas; Richard J Hayes; Laith J Abu-Raddad
Journal:  Emerg Themes Epidemiol       Date:  2008-07-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.